
    
      The total duration per patient is up to 5.5 years.

      As per Study Investigator discretion, patients can be treated with additional courses of
      alemtuzumab or any commercialized disease modifying treatment.

      All patients who complete CAMM03409 will be allowed into the study, which may include
      specific vulnerable populations. If the investigator decides to treat a patient with a course
      of alemtuzumab, appropriate cautionary measures will be applied as indicated in the approved
      labelling, or, in ex-EU countries where Lemtrada is not approved, according to the
      investigator's brochure.
    
  